Latest News

OSLO, Norway, May 6, 2019 - Photocure ASA (OSE: PHO) today announced key data presented at the 2019 American Urological Association (AUA) Annual Meeting in Chicago.  Session presentations and a poster presentation discussed Blue Light Cystoscopy (BLC™) with Cysview.

Oslo, Norway, 30 April 2019: Photocure ASA announced today that a study published in World Journal of Urology, shows that patients who undergo bladder tumor resection with Blue Light Cystoscopy (BLC™) with Hexvix® exhibit improved outcomes even if they progress to disease stages which require radical cystectomy.

Oslo, Norway April 25th, 2019, Photocure ASA (Photocure, PHO: OSE), today announced an Expert Consensus on the optimal use of Blue Light Cystoscopy (BLC™) with Cysview® in Nature Reviews Urology.

Oslo, 17 April 2019: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 9 May 2019 at 17:00 hours (CET).

Oslo, 17 April 2019: Photocure ASA (OSE: PHO), has published the annual accounts and annual report for the financial year 2018.

Oslo, Norway, April 9, 2019:

Photocure ASA (PHO:OSE) today announces that Blue Light Cystoscopy (BLC™) procedures with Hexvix® will be reimbursed in Australia from May 1, 2019, following new listings from the Australian Government Department of Health.

Oslo, Norway, April 8, 2019: Photocure ASA (PHO:OSE) announced today that Photocure will be exhibiting Blue Light Cystoscopy (BLC™) with Cysview in Booth 2214, during the American Urological Association Meeting (AUA 2019) in Chicago  May 3rd-6th.

A large survey posted by the Bladder Cancer Advocacy Network (BCAN) and published in UroToday revealed a growing preference for Cysview^®

A large survey posted by the Bladder Cancer Advocacy Network (BCAN) and published in UroToday revealed a growing preference for Cysview®.

(The press release is updated with the following sentences: This means that in this survey more than 50% of the patients said they were willing to pay $100 or more out of their own pocket to get the blue light procedure. This is not linked to the price or reimbursement of the Cysview® drug. From January 2019 Cysview® for use in the office with flexible scopes is reimbursed.)

Oslo, Norway March 19, 2019, Photocure ASA (PHO:OSE), is pleased to announce that Blue Light Cystoscopy (BLC™) with Hexvix® was presented at the European Association of Urology (EAU) congress held in Barcelona, Spain, March 15th -18th. The EAU annual meeting is one of the largest international meetings in the urology calendar, showcasing the latest and most relevant knowledge in urology with more than 14,000 urologists and exhibitors from over 110 countries.

Oslo, Norway, 8 March 2019: Photocure will on Wednesday 13 March 2019 13:00 (CET) stream a Q&A live session with Photocure's President and CEO Dan Schneider via the Facebook group "Photocure Investors" and https://www.facebook.com/groups/aksjekunnskap/ and https://www.facebook.com/groups/Aksjeforum/

It will be open for questions before and during the session. Pål Falck, health analytics at Arctic, will moderate the session.

Oslo, Norway, 27 February 2019: Photocure ASA (OSE:PHO), today reported a revenue growth of 76% in local currency for the U.S. market in the fourth quarter of 2018, contributing to Hexvix/Cysview revenues of NOK 46.3 million (Q4 2017: NOK 39.4) and a recurring EBITDA of NOK -4.1 million (NOK -13.1 million). The company maintains its 2020 forecasted revenue range of USD 20-25 million in the U.S., up from USD 7.8 million in 2018, and sees significant continued revenue growth and profit opportunities in the U.S. market beyond 2020.

Reference is made to the announcement on 14 February 2019 in respect of a capital increase of 17,379 new shares following the execution of the employee long-term incentive program for restricted shares in the company.

Photocure will present its fourth quarter report on Wednesday 27 February 2019 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).